Similarly, immune checkpoint blockades (ICBs), oncolytic viruses, and tumor vaccines rely on cGAS-STING to amplify immune responses, particularly T-cell activation and dendritic cell (DC) cross-presentation [11–14]. This evidence concerns the gene STING1 and neoplasm.